Crocè, Saveria
 Distribuzione geografica
Continente #
NA - Nord America 9.094
EU - Europa 5.329
AS - Asia 1.965
SA - Sud America 94
AF - Africa 81
Continente sconosciuto - Info sul continente non disponibili 15
OC - Oceania 13
Totale 16.591
Nazione #
US - Stati Uniti d'America 8.957
IT - Italia 1.268
PL - Polonia 1.037
SE - Svezia 811
CN - Cina 622
UA - Ucraina 595
HK - Hong Kong 515
SG - Singapore 482
DE - Germania 374
RU - Federazione Russa 240
FI - Finlandia 227
BG - Bulgaria 191
TR - Turchia 162
IE - Irlanda 155
CA - Canada 128
GB - Regno Unito 126
BR - Brasile 65
CH - Svizzera 63
FR - Francia 59
SN - Senegal 54
NL - Olanda 52
BE - Belgio 43
VN - Vietnam 43
IN - India 25
KR - Corea 25
CZ - Repubblica Ceca 18
AT - Austria 17
EG - Egitto 14
JP - Giappone 13
ID - Indonesia 12
IR - Iran 12
ES - Italia 11
PH - Filippine 11
AU - Australia 10
EU - Europa 10
RO - Romania 10
AR - Argentina 9
DK - Danimarca 7
IL - Israele 7
MX - Messico 6
A2 - ???statistics.table.value.countryCode.A2??? 5
BD - Bangladesh 5
CL - Cile 5
KE - Kenya 5
LT - Lituania 5
CO - Colombia 4
EC - Ecuador 4
HR - Croazia 4
NG - Nigeria 4
PK - Pakistan 4
TW - Taiwan 4
AM - Armenia 3
GE - Georgia 3
GR - Grecia 3
NP - Nepal 3
NZ - Nuova Zelanda 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
UY - Uruguay 3
ZA - Sudafrica 3
AE - Emirati Arabi Uniti 2
BA - Bosnia-Erzegovina 2
CU - Cuba 2
KG - Kirghizistan 2
LK - Sri Lanka 2
TH - Thailandia 2
AZ - Azerbaigian 1
BO - Bolivia 1
BT - Bhutan 1
EE - Estonia 1
HU - Ungheria 1
IQ - Iraq 1
MA - Marocco 1
MY - Malesia 1
NO - Norvegia 1
PA - Panama 1
PE - Perù 1
PT - Portogallo 1
PY - Paraguay 1
RS - Serbia 1
TJ - Tagikistan 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 16.591
Città #
Warsaw 1.026
Woodbridge 969
Fairfield 933
Ann Arbor 875
Chandler 828
Houston 817
Jacksonville 554
Ashburn 546
Hong Kong 505
Wilmington 459
Seattle 422
Trieste 420
Singapore 329
Cambridge 304
Princeton 259
Boardman 235
Sofia 191
Beijing 165
Dublin 151
Izmir 151
Columbus 149
Toronto 104
Moscow 101
Dearborn 79
Milan 69
San Diego 66
Falls Church 58
Santa Clara 57
Dakar 54
Bern 52
Helsinki 52
Venezia 42
Brussels 40
Dong Ket 40
Redmond 40
Redwood City 38
Des Moines 36
Chicago 29
Krefeld 29
Udine 28
Rome 27
Verona 25
Shanghai 22
Bremen 20
Grafing 20
Munich 20
Mestre 19
Norwalk 19
Seoul 19
Phoenix 18
Düsseldorf 17
Los Angeles 17
Guangzhou 16
Jinan 16
Kunming 16
Ottawa 15
Washington 15
Fremont 14
Nuremberg 14
Vienna 14
London 13
Amsterdam 12
Brno 12
Buffalo 12
Nanchang 12
Nanjing 12
Dallas 11
Shenzhen 11
Venice 11
Hefei 10
Oklahoma City 10
Shenyang 10
São Paulo 10
Naples 9
New York 9
Turin 9
Fuzhou 8
Menlo Park 8
New Haven 8
Padova 8
Palermo 8
Taiyuan 8
Duino-Aurisina 7
Florence 7
Gattaran 7
Jakarta 7
Lozzo di Cadore 7
Parma 7
Pune 7
San Vito Al Tagliamento 7
Wuhan 7
Alba 6
Central 6
Edinburgh 6
Kocaeli 6
Maniago 6
Piscataway 6
Stockholm 6
Tel Aviv 6
Basel 5
Totale 12.002
Nome #
MBL2 Genetic Variants in HCV Infection Susceptibility, Spontaneous Viral Clearance and Pegylated Interferon Plus Ribavirin Treatment Response 386
The role of multipotent cancer associated fibroblasts in hepatocarcinogenesis 359
Transcriptional Up-Regulation of APE1/Ref-1 in hepatic tumor: Role in hepatocytes resistance to oxidative stress and apoptosis 342
Serum Stem Cell Growth Factor Beta for the Prediction of Therapy Response in Hepatocellular Carcinoma 315
Adverse reactions of direct-acting antiviral agents in HCV patients: Our experience 306
Evaluation of spleen stiffness in healthy volunteers using point shear wave elastography 291
MicroRNAs as Regulators of Neo-Angiogenesis in Hepatocellular Carcinoma 286
The Role of Liver and Spleen Elastography in the Screening of Esophageal Varices in Patients with Liver Cirrhosis: Do We Really Need Endoscopy? 278
Serum AP-endonuclease 1 (sAPE1) as novel biomarker for hepatocellular carcinoma 262
Gut microbiota characterisation in obese patients before and after bariatric surgery 236
HBV, HCV, and TTV detection by in situ polymerase chain reaction could reveal occult infection in hepatocellular carcinoma: comparison with blood markers 195
A new insight on the stem cell growth factor beta as astrong predictor of therapy response in hepatocellular carcinoma 189
Abnormal apolipoprotein B pre-mRNA splicing in patients with familial hypobetalipoproteinaemia 181
Role of SERPINB3 like serological and molecular biomarker into NASH development and progression 178
Anatomy of Basal Ganglia and Thalamus 176
NOVEL BIOMARKERS FOR THE DIAGNOSIS OF LIVER FIBROSIS IN A HIGHLY RISK NAFLD COHORT in IFSO 2017 22(nd) World Congress 175
Identification and evaluation of novel non-invasive biomarkers for non-alcoholic fatty liver disease 173
CD209 promoter polymorphisms associate with HCV infection and pegylated-interferon plus ribavirin treatment response 172
1H-NMR Spectroscopic Studies of Lipid Extracts from Human Fatty Liver 169
Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma. 168
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. 166
TACE with cone beam computed tomography is more effective than traditional technique in BCLC A HCC patients ineligible to surgery 158
Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. 157
A simple in silico strategy identifies candidate biomarkers for the diagnosis of liver fibrosis in morbidly obese subjects 154
Changing molecular epidemiology of hepatitis C virus infection in Northeast Italy. 149
Cohort effect of HCV infection in liver cirrhosis assessed by a 25 years study 148
null 146
Blood flow changes in hepatocellular carcinomas after the administration of Thaliodomide by reperfusion kinetics during microbubble infusion: Preliminary results. 146
Hepatitis B virus genotypes, core promoter variants, and precore stop codonvariants in patients infected chronically in North-Eastern Italy. 144
null 143
Hepatic cancer stem cells and drug resistance: relevance in targeted therapies of hepatocellular carcinoma 142
The Next Generation Sequencing (NGS) platform in the assessment of the gut microbiota in bariatric surgery. 141
Clinical patterns of hepatocellular carcinoma in non alcoholic fatty liver disease: A multicenter prospective study 140
Bariatric surgery drives major rearrangements of the intestinal microbiota including the biofilm composition. 139
Spleen Stiffness Probability Index (SSPI): A simple and accurate method to detect esophageal varices in patients with compensated liver cirrhosis 139
Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients 138
Treatment options in Western hepatocellular carcinoma: A prospective study of 224 patients 137
A comparative characterization of the circulating miRNome in whole blood and serum of HCC patients 134
null 133
PREVALENCE OF CHRONIC LIVER-DISEASE IN THE GENERAL-POPULATION OF NORTHERN ITALY - THE DIONYSOS STUDY 133
MiR-3201 as a Prognostic Blood Biomarker for Curative Treatments in Hepatocellular Carcinoma 132
null 129
Gene expression of ABC proteins in hepatocellular carcinoma, perineoplastic tissue and liver diseases 129
null 129
HLA-G regulatory polymorphisms are associated with susceptibility to HCV infection 128
null 125
Visual impairments and attention in parkinson's disease 125
Distribution of stem cells and cancer stem cells markers in liver pathologies and their indication to the response of therapy 124
Evaluation with contrast enhanced US of perfusion changes in untreatable hepatocellular carcinoma after thalidomide administration: preliminary results 123
The plasticity of the stem cells in the hepatocarcinogenesis and metastasis: study in vitro and in vivo 123
Drug-induced acute cholestatic liver damage in a patient with mutation of UGT1A1 121
Repeated double cross-validation applied to the PCA-LDA classification of SERS spectra: a case study with serum samples from hepatocellular carcinoma patients 121
Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology. 2009 Oc FI, 9;9:75. 120
Analysis of p53 and ras gene mutations in hepatocellular carcinoma from a Western country 120
Weighted miRNA co-expression networks analysis identifies circulating miRNA predicting overall survival in hepatocellular carcinoma patients 120
null 119
Stem cells in the development of hepatocellular carcinoma: identification and expression 118
Deep brain stimulation of the subthalamus: Neuropsychological effects 117
Clinical update on non-alcoholic fatty liver disease and steatohepatitis 115
High fecal calprotectin levels are associated with SARS-CoV-2 intestinal shedding in COVID-19 patients: A proof-of-concept study 115
Cross talk between multipotent stem-like cells and cancer cells in hepatocellular carcinoma 114
Antibiotics and Liver Cirrhosis: What the Physicians Need to Know 114
Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease 113
Human leucocyte interferon-alpha in the treatment of chronic hepatitis C 110
null 110
null 110
null 107
null 105
Clinical and virological features of acute HBV-related hepatitis in southern vietnam 105
null 101
null 101
null 100
The role of elastography in alcoholic liver disease: fibrosis staging and confounding factors, a review of the current literature 98
Cirrosi biliare primitiva (CBP) asintomatica: trattamento con acido ursidesossicolico (UDCA). Risultati preliminari dopo 12 mesi. 97
Characterization of focal liver lesions by pulse inversion harmonic imaging (PIHI) with Levovist in patients with cirrhosis. 97
Scelte terapeutiche e trattamento con sorafenib nell'epatocarcinoma: Analisi finale dello studio GIDEON in Italia 97
null 96
Severity of liver disease with different hepatitis C viral clones. 95
Spontaneous rectal perforation in a patient with SARS–CoV-2 infection 92
null 90
null 90
Spontaneous porto-femoral shunting in long-standing portal hypertension 89
Evaluation of liver parenchymal blood flow with contrast-enhanced US: preliminary results in healthy and cirrhotic patients 88
Hepatocellular carcinoma in the non-cirrhotic liver in Northern Italy: a retrospective study 88
null 87
Incidence and natural history of hepatocellular carcinoma and liver cirrhosis in Italy. A lesson from Trieste 86
Diverticular Disease and Rifaximin: An Evidence-Based Review 84
Antibody pattern of HCV infection and hepatocellular carcinoma in Itakly: A case control study 83
Peritoneal Tuberculosis during Infliximab Treatment in a Patient with Ulcerative Colitis Despite a Negative Quantiferon Test 83
COVID-19-Induced Thrombosis in Patients without Gastrointestinal Symptoms and Elevated Fecal Calprotectin: Hypothesis Regarding Mechanism of Intestinal Damage Associated with COVID-19 82
Optimization of point-shear wave elastography by skin-to-liver distance to assess liver fibrosis in patients undergoing bariatric surgery 82
Behind the Decrease of Liver Stiffness After Successful Hepatitis C Virus Eradication with Direct-Acting Antiviral Agents 81
Alanine aminotransferase and spleno-portal dynamics affect spleen stiffness measured by point shear-wave elastography in patients with chronic hepatitis C in the absence of significant liver fibrosis 80
null 79
Variazioni della perfusione dell’epatocarcinoma dopo trattamento con talidomide 79
A story of liver and gut microbes: How does the intestinal flora affect liver disease? A review of the literature 79
Elastography: where are we now? 79
Epidemiologia del carcinoma epatocellulare 78
null 78
Circulatory mirna as a biomarker for therapy response and disease-free survival in hepatocellular carcinoma 77
Totale 13.881
Categoria #
all - tutte 54.939
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.939


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.032 0 0 0 0 0 0 0 315 247 162 209 99
2020/20212.303 186 141 193 253 213 233 184 198 106 215 120 261
2021/20221.868 60 98 226 204 58 133 103 126 213 167 103 377
2022/20232.513 216 280 167 346 224 454 55 263 321 38 96 53
2023/20241.574 116 90 73 101 171 135 270 314 30 50 130 94
2024/20251.787 64 71 185 363 322 332 316 134 0 0 0 0
Totale 17.272